2018年12月3日 · The peptide drug GM604 (GM6 or Alirinetide) was developed as a candidate ALS therapy, which has demonstrated safety and good drug-like properties with a favorable …

The drug, referred to as GM604, is the endogenous embryonic stage growth factor regulator signaling multi-target peptide drug that can modulate hundreds of ALS related genes. …

Alirinetide (GM604) is an oligopeptide containing 6 amino acids. Alirinetide can cross the blood-brain barrier and can be used for the research of multiple neurodegenerative diseases [1]. …

2024年11月15日 · GM604 is an experimental therapy that’s designed to slow disease progression in people with amyotrophic lateral sclerosis (ALS). It’s given via intravenous injection into the …

2017年3月7日 · GM604 decreased plasma levels of key ALS biomarkers relative to the placebo group (TDP-43, P = 0.008; Tau, P = 0.037; SOD1, P = 0.009). The advanced ALS patient in …

GM604 controls and modulates over many known and significant ALS genes with positive effects interactively and dynamically through multiple pathways, and up to twenty-two biological …

2020年6月12日 · The GM604 (Alirinetide) synthetic linear peptide sequence (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH) evaluated in our study was determined from these sequences and experiments …

In this study, GM604 or vehicle were administered to mice following an experimentally induced stroke and reperfusion. Treatment with GM604 was associated with lower markers of …

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Oct-Nov;17 (7-8):617-621. doi: 10.3109/21678421.2016.1164940. Epub 2016 Apr 4.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that lacks effective treatment options. Genervon has discovered and developed GM604 (GM6) as a potential ALS …